Diagnostic accuracy of 99mTc-sestamibi SPECT/CT for detecting renal oncocytomas and other benign renal lesions: a systematic review and meta-analysis

Conclusion99mTc-sestamibi SPECT/CT demonstrates a high sensitivity and specificity for characterizing benign and low-grade renal lesions. This test can help improve the diagnostic confidence for patients with indeterminate renal masses being considered for active surveillance.
Source: Abdominal Imaging - Category: Radiology Source Type: research

Related Links:

ConclusionFU imaging with111In-girentuximab-SPECT is feasible after ccRCC cryoablation and may contribute to early detection of residual or recurrent disease.
Source: European Journal of Nuclear Medicine and Molecular Imaging - Category: Nuclear Medicine Source Type: research
Conclusions: In conclusion, there is a difference in the average scores of the original images and the reframed images of highest rating. The results shows it is possible to reduce imaging time by 20%. In addition, using a smaller matrix size on the CZT camera can significantly improve image quality. List mode data acquisition and post-acquisition resorting allowed protocol modifications to be evaluated prior to implementation in imaging oncocytoma, which effectively reduce patient motion and acquisition time.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Technologist Student Papers I Source Type: research
Conclusions: 99mTc-MIBI SPECT/CT appears to be of value in distinguishing benign renal tumors from RCC. This imaging method can be used to diagnose two types of benign kidney tumors. Our experiment may be eventually used to help better evaluate patients diagnosed with a solid renal mass. In summary, 99mTc-MIBI SPECT/CT is a promising imaging test for the noninvasive diagnosis of solid renal tumors. However, larger numbers are needed to precisely define the sensitivity and specificity of this test. Keywords: Oncocytoma, Angiomyolipoma, Renal Cell Carcinoma,99mTc-MIBI, SPECT/CT
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Prostate/GU Imaging Posters Source Type: research
Conclusion: The high ICC values indicate a strong agreement among SUV measurements for patients with solid renal lesions undergoing a 99mTc-Sestamibi SPECT/CT examination not only in measurements of the same reader but also between two different readers. PMID: 31019039 [PubMed - as supplied by publisher]
Source: Journal of Nuclear Medicine Technology - Category: Nuclear Medicine Tags: J Nucl Med Technol Source Type: research
Authors: Kuusk T, De Bruijn R, Brouwer OR, De Jong J, Donswijk M, Hendricksen K, Horenblas S, Jóźwiak K, Prevoo W, Valdés Olmos RA, Van Der Poel HG, Van Rhijn BW, Wit EM, Bex A Abstract OBJECTIVE: To investigate the rate of occult SN metastases, oncological outcome, and association of recurrence with the pattern of lymphatic tumour drainage in RCC. MATERIALS AND METHODS: A pooled RCC sub-group analysis was conducted of secondary endpoints from a published feasibility and a phase II prospective single-arm SN study to investigate oncological outcome. Patients with cT1-3 (
Source: Scandinavian Journal of Urology - Category: Urology & Nephrology Tags: Scand J Urol Source Type: research
Conclusion: This first in man study shows that tumor-targeted dual-modality imaging using 111In-DOTA-girentuximab-IRDye800CW is safe and can be used for intraoperative guidance of ccRCC resection.
Source: Theranostics - Category: Molecular Biology Authors: Tags: Research Paper Source Type: research
ConclusionThe diagnosis and characterisation of SRM and response assessment following targeted therapy for advanced RCC are key challenges which warrant further research.
Source: World Journal of Urology - Category: Urology & Nephrology Source Type: research
Conclusion [Tc-99m]-TOC imaging should be used as an initial imaging approach in detection and follow-up of VHL manifestations, screening of asymptomatic gene carriers, and in diagnosis of pheochromocytoma, PNET, CNS hemangioblastomas and RCC.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Endocrine/Neuroendocrine Posters Source Type: research
A recent reassessment of the pathology for the case described in this report has facilitated new perspectives, and our objective is to provide an update that should be informative.1 The patient was a 12-year-old girl with 2 right lower pole renal tumors, both relatively small ( ≤2.0 cm) and solid, and only demonstrating modest enhancement. Genetic testing revealed a defect in the fumarate hydratase (FH) gene, which is commonly altered in the hereditary leiomyomatosis renal cell carcinoma (HLRCC) syndrome, where aggressive renal tumors are typically seen.
Source: Urology - Category: Urology & Nephrology Authors: Source Type: research
A recent reassessment of the pathology for the case described in this report has facilitated new perspectives, and our objective is to provide an update that should be informative.1 The patient was a 12-year-old girl with 2 right lower pole renal tumors, both relatively small ( ≤2.0 cm) and solid, and only demonstrating modest enhancement. Genetic testing revealed a defect in the fumarate hydratase (FH) gene, which is commonly altered in the hereditary leiomyomatosis renal cell carcinoma (HLRCC) syndrome, where aggressive renal tumors are typically seen.
Source: Urology - Category: Urology & Nephrology Authors: Tags: Letters to the Editor Source Type: research
More News: Cancer & Oncology | Carcinoma | Databases & Libraries | Kidney Cancer | Radiology | Renal Cell Carcinoma | SPECT | Study